March 3 at 10:20 a.m.
Filed under:
Pharmaceuticals
By Associated Press
BioSante Pharmaceuticals Inc. said Thursday its potential pancreatic cancer treatment met key goals in a midstage study.
The company’s stock surged 32 cents, or 16 percent, to $2.35 in premarket trading.
The company said a newly published study showed the vaccine increased the median survival rate of patients by more than 25 percent to 24.8 months. The results were published in the February issue of the Annals of Surgery and involved 60 patients undergoing treatment at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore. Get the full story »
Dec. 30, 2010 at 9:15 a.m.
Filed under:
Investing
By Alejandra Cancino
Lincolnshire-based BioSante Pharmaceuticals has signed a $18 million deal with several investors to sell 10.6 million shares of its common stock. Get the full story »
June 28, 2010 at 7:52 a.m.
Filed under:
Exchanges,
Pharmaceuticals,
Stock activity
By Tribune staff report
BioSante Pharmaceuticals Inc. said today it has been added to the broad-market Russell 3000 Index as part of Russell Investments’ recent reconstitution of its comprehensive set of U.S. and global equity indexes after market close Friday. Get the full story »
